Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA’s Fairy Godmother: Woodcock Steps Into Breach As Acting CDER Chief

Executive Summary

Faced with the departure of Steven Galson as CDER director just as major new drug safety authorities have been bestowed upon FDA, Commissioner Andrew von Eschenbach has turned to former CDER director Janet Woodcock to provide a practiced hand on the wheel of change until a permanent replacement can be found

You may also be interested in...



Life After Woodcock: US FDA Drug Center’s Leadership Transition

The elevation of the US FDA’s top drug regulator, Janet Woodcock, to oversee COVID-19 response efforts is being framed a temporary step as part of the crisis response. But it is also a try-out for the most significant leadership transition in drug regulation in the US in a generation.

Former CDER Chief Galson Moving To Amgen

Galson, who went to FDA in 2001 to deal with post-marketing surveillance issues, will arrive in time for Aranesp advisory committee meeting.

Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss

Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains deeply committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects

Related Content

UsernamePublicRestriction

Register

PS048843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel